Pakistan and China have taken another significant step toward strengthening their partnership in the healthcare sector by signing 22 investment agreements worth approximately $629.5 million during the Pakistan-China Pharmaceutical & Healthcare B2B Investment Conference.
The agreements cover a wide range of areas, including vaccine production, active pharmaceutical ingredients (APIs), pharmaceutical manufacturing, medical devices, and clinical trials.
In addition to these agreements, both sides also signed 84 memorandums of understanding (MoUs) valued at nearly $800 million, many of which are expected to develop into formal investment projects in the coming months.
Speaking at the conference, Federal Health Minister Mustafa Kamal said the collaboration is aimed at transforming Pakistan’s pharmaceutical and healthcare industry.
He noted that the partnerships will help increase local vaccine production, reduce the country’s dependence on imported APIs, attract foreign direct investment, encourage technology transfer, expand pharmaceutical exports, and generate new employment opportunities.
The initiative is also expected to strengthen Pakistan’s healthcare infrastructure and improve long-term health security through greater self-reliance and innovation in the medical sector.
